StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
28
Publishing Date
2023 - 12 - 11
1
2023 - 12 - 07
1
2023 - 12 - 06
1
2023 - 10 - 31
1
2023 - 08 - 25
1
2023 - 07 - 10
1
2023 - 03 - 21
1
2023 - 03 - 16
2
2023 - 02 - 06
1
2022 - 12 - 20
1
2022 - 07 - 25
1
2022 - 06 - 22
1
2022 - 05 - 27
1
2022 - 04 - 06
1
2022 - 03 - 24
1
2021 - 12 - 22
3
2021 - 12 - 20
1
2021 - 11 - 01
1
2021 - 10 - 29
1
2021 - 09 - 22
1
2021 - 06 - 08
1
2021 - 06 - 01
1
2021 - 04 - 12
1
2021 - 04 - 09
1
2021 - 03 - 22
1
Sector
Health technology
28
Tags
America
67
Antibody
13
Application
12
Approval
21
Biosimilar
39
Breast
13
Cancer
106
Covid
17
Covid-19
12
Device
14
Diabetes
18
Diagnostics
19
Disease
76
Drug
115
Drug delivery
11
Earnings
21
Europe
17
Expansion
11
Expected
35
Eye
21
Fda
28
Financial
24
Financial results
13
Gene therapy
11
Global
229
Growing
47
Growth
262
Health
19
Immunotherapy
12
Kisqali
11
Leukemia
12
Liver
20
Market
599
N/a
1115
Novartis
133
Patent
13
People
20
Pharma
17
Pharmaceuticals
17
Pipeline
12
Positive
19
Potential
13
Reach
34
Report
195
Research
129
Respiratory
15
Results
52
Risk
11
Sales
11
Sclerosis
13
Set
16
Study
17
T-cell
12
Technology
14
Therapeutics
114
Therapy
89
Treatment
137
Trial
25
Vaccine
16
Year
12
Entities
22nd century group, inc
10
Abbott laboratories
79
Abbvie inc.
42
Acer therapeutics inc.
12
Adma biologics inc
18
Amgen inc.
23
Amneal pharmaceuticals, inc.
15
Ani pharmaceuticals, inc.
17
Apyx medical corporation
12
Aquestive therapeutics, inc.
15
Ardelyx, inc.
11
Arrival
10
Astellas pharma inc
17
Avenue therapeutics, inc.
10
Becton, dickinson and company
13
Beigene, ltd.
16
Biogen inc.
32
Biomarin pharmaceutical inc.
10
Biontech se
24
Bluebird bio, inc.
13
Boston scientific corporation
11
Brainstorm cell therapeutics inc.
14
Bristol-myers squibb company
20
Coherus biosciences, inc.
23
Eagle pharmaceuticals, inc.
11
Eli lilly and company
71
Eyenovia, inc.
13
Fortress biotech, inc.
14
Gilead sciences, inc.
21
Glaxosmithkline plc
14
Incyte corporation
23
Inhibikase therapeutics, inc.
10
Ionis pharmaceuticals, inc.
13
Jaguar health, inc.
16
Johnson & johnson
227
Medtronic plc
28
Merck & company, inc.
36
Mesoblast limited
15
Moderna, inc.
13
Novartis ag
28
Novavax, inc.
11
Novo nordisk a/s
11
Ocugen, inc.
15
Orange
63
Perrigo company
90
Pfizer, inc.
74
Reata pharmaceuticals, inc.
12
Regeneron pharmaceuticals, inc.
50
Sanofi
236
Seagen inc.
10
Soligenix, inc.
14
Sorrento therapeutics, inc.
21
T2 biosystems, inc.
14
Takeda pharmaceutical company limited
17
Teva pharmaceutical industries ltd
22
Thermo fisher scientific inc
16
Tonix pharmaceuticals holding corp.
12
Verrica pharmaceuticals inc.
13
Vertex pharmaceuticals incorporated
14
Veru inc.
14
Symbols
ALNY
1
AMGN
1
ERAS
1
GMAB
1
INCY
2
JNJ
1
NVS
28
NVSEF
22
SGEN
1
Exchanges
Nasdaq
25
Nyse
28
Crawled Date
2023 - 12 - 11
1
2023 - 12 - 08
1
2023 - 12 - 06
1
2023 - 10 - 31
1
2023 - 08 - 25
1
2023 - 07 - 10
1
2023 - 03 - 21
1
2023 - 03 - 16
2
2023 - 02 - 06
1
2022 - 12 - 20
1
2022 - 07 - 25
1
2022 - 06 - 23
1
2022 - 05 - 27
1
2022 - 04 - 06
1
2022 - 03 - 24
1
2021 - 12 - 23
1
2021 - 12 - 22
2
2021 - 12 - 20
1
2021 - 11 - 01
1
2021 - 10 - 29
1
2021 - 09 - 22
1
2021 - 06 - 08
1
2021 - 06 - 01
1
2021 - 04 - 12
1
2021 - 04 - 09
1
2021 - 03 - 22
1
Crawled Time
00:00
3
01:00
3
06:00
2
07:00
2
12:00
3
13:00
1
15:00
2
18:00
1
20:00
2
21:00
3
23:00
6
Source
www.biospace.com
10
www.globenewswire.com
16
www.prnewswire.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Fda
entities :
Novartis ag
save search
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
Published:
2023-12-11
(Crawled : 13:00)
- globenewswire.com
ERAS
|
$1.77
-1.12%
270K
|
|
3.21%
|
O:
1.07%
H:
0.0%
C:
-2.65%
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
-3.34%
|
O:
0.75%
H:
0.55%
C:
0.27%
fda
melanoma
granted
designation
advanced
FDA Approves Bio-Thera Solutions' Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®
Published:
2023-12-07
(Crawled : 00:00)
- biospace.com/
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
-4.09%
|
O:
-0.97%
H:
0.3%
C:
-0.19%
avzivi
fda
biosimilar
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
Published:
2023-12-06
(Crawled : 00:00)
- globenewswire.com
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
-4.01%
|
O:
0.52%
H:
0.18%
C:
-0.43%
fabhalta
fda
first
approval
offering
novartis
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
Published:
2023-10-31
(Crawled : 21:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
2.99%
|
O:
2.52%
H:
0.04%
C:
0.04%
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
-0.53%
|
O:
0.16%
H:
0.7%
C:
0.57%
cosentyx
fda
treatment
novartis
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Published:
2023-08-25
(Crawled : 06:00)
- globenewswire.com
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
-7.7%
|
O:
0.67%
H:
0.37%
C:
0.26%
tyruko
fda
biosimilar
approval
sclerosis
US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease
Published:
2023-07-10
(Crawled : 12:00)
- biospace.com/
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
-1.74%
|
O:
1.44%
H:
0.73%
C:
0.48%
leqvio
fda
disease
treatment
risk
novartis
heart
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Published:
2023-03-21
(Crawled : 15:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
36.78%
|
O:
1.89%
H:
0.0%
C:
-1.15%
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
11.57%
|
O:
0.25%
H:
0.19%
C:
0.04%
hyrimoz
fda
biosimilar
approval
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
Published:
2023-03-16
(Crawled : 23:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
36.55%
|
O:
-0.17%
H:
0.0%
C:
0.0%
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
12.44%
|
O:
-0.02%
H:
0.39%
C:
-0.69%
fda
approved
tafinlar
cancer
novartis
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
Published:
2023-03-16
(Crawled : 07:00)
- prnewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
39.15%
|
O:
1.16%
H:
0.73%
C:
0.73%
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
13.37%
|
O:
0.18%
H:
0.77%
C:
0.64%
illuccix
fda
therapy
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
Published:
2023-02-06
(Crawled : 07:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
31.25%
|
O:
-0.44%
H:
0.0%
C:
-2.93%
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
8.42%
|
O:
-0.33%
H:
0.15%
C:
-0.12%
AMGN
|
$267.41
1.77%
1.4M
|
Health Technology
|
8.06%
|
O:
0.08%
H:
0.59%
C:
-0.62%
fda
biosimilar
application
license
Recombinant Adeno-Associated Virus (rAAV) Technology Pioneered by AskBio's Dr. Jude Samulski is Key Component of All FDA Approved AAV Gene Therapeutics
Published:
2022-12-20
(Crawled : 23:00)
- biospace.com/
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
3.2%
|
O:
-0.18%
H:
0.61%
C:
0.38%
fda
approved
technology
virus
therapeutics
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
Published:
2022-07-25
(Crawled : 06:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
34.65%
|
O:
3.12%
H:
0.06%
C:
0.06%
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
8.4%
|
O:
0.06%
H:
0.31%
C:
0.19%
fda
biosimilar
ema
sclerosis
multiple sclerosis
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
Published:
2022-06-22
(Crawled : 00:00)
- globenewswire.com
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
14.43%
|
O:
0.3%
H:
0.0%
C:
0.0%
fda
novartis
approval
tafinlar
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Published:
2022-05-27
(Crawled : 23:00)
- globenewswire.com
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
Email alert
Add to watchlist
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
Email alert
Add to watchlist
kymriah
fda
novartis
car-t
therapy
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Published:
2022-04-06
(Crawled : 01:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
5.6%
|
O:
0.37%
H:
0.06%
C:
0.06%
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
5.57%
|
O:
0.78%
H:
2.05%
C:
2.01%
vijoice
treatment
fda
novartis
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer
Published:
2022-03-24
(Crawled : 01:00)
- prnewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
7.56%
|
O:
-1.47%
H:
0.0%
C:
-1.11%
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
9.06%
|
O:
0.71%
H:
0.0%
C:
0.0%
novartis
treatment
fda
therapy
cancer
prostate cancer
Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis
Published:
2021-12-22
(Crawled : 01:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
9.13%
|
O:
1.23%
H:
0.0%
C:
0.0%
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
7.84%
|
O:
0.56%
H:
0.43%
C:
-0.15%
cosentyx
novartis
treatment
fda
fda approval
approval
children
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
Published:
2021-12-22
(Crawled : 23:00)
- biospace.com/
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
8.25%
|
O:
-0.55%
H:
0.99%
C:
0.92%
ALNY
|
News
|
$145.89
0.5%
170K
|
Health Technology
|
-27.27%
|
O:
-5.24%
H:
2.44%
C:
-0.93%
leqvio
fda
fda approval
approval
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
Published:
2021-12-22
(Crawled : 23:00)
- biospace.com/
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
8.25%
|
O:
-0.55%
H:
0.99%
C:
0.92%
leqvio
novartis
fda
cholesterol
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
Published:
2021-12-20
(Crawled : 23:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
9.07%
|
O:
-0.06%
H:
0.0%
C:
0.0%
NVS
|
$93.81
1.34%
1.2M
|
Health Technology
|
9.06%
|
O:
0.56%
H:
0.3%
C:
0.19%
fda
application
license
biosimilar
← Previous
1
2
Next →
Gainers vs Losers
71%
29%
Top 10 Gainers
AGBA
|
News
|
$1.27
217.5%
120M
|
Finance
EGOX
|
$0.0503
39.72%
320M
|
RWOD
|
$10.52
31.56%
5.9M
|
n/a
ZCMD
|
$1.905
31.38%
30M
|
Commercial Services
NVFY
|
$2.71
28.44%
31M
|
Consumer Durables
MRDB
4
|
$0.536
27.65%
2M
|
n/a
BSFC
|
$0.0822
27.64%
75M
|
Manufacturing
TPET
|
$0.4121
25.68%
45M
|
n/a
INDO
|
$5.1
25.0%
15M
|
Energy Minerals
CHRO
|
$1.53
24.9%
100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.